Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jaume Capdevila

Showing results (131-140 of 192) with videos related to

Pageof 20
Sort By:
BMC Cancer|July 4, 2015
Evaluation of the efficacy and safety of lanreotide in combination with targeted therapies in patients with neuroendocrine tumours in clinical practice: a retrospective cross-sectional analysisJaume Capdevila, Isabel Sevilla, Vicente Alonso, et al.
The Oncologist|December 16, 2017
Phase II Study of BEZ235 versus Everolimus in Patients with Mammalian Target of Rapamycin Inhibitor-Naïve Advanced Pancreatic Neuroendocrine TumorsRamon Salazar, Rocio Garcia-Carbonero, Steven K Libutti, et al.
European Journal of Cancer (Oxford, England : 1990)|February 3, 2026
Larotrectinib in patients with tropomyosin receptor kinase fusion solid tumors in Spain (SPAINTRK)Jorge Hernando, Carlos Lopez, Alejandro Garcia-Alvarez, et al.
Molecular Oncology|June 16, 2017
Analysis of mutant allele fractions in driver genes in colorectal cancer - biological and clinical insightsRodrigo Dienstmann, Elena Elez, Guillem Argiles, et al.
Neuroendocrinology|August 31, 2013
Prognostic factors and long-term outcome of pancreatic neuroendocrine neoplasms: Ki-67 index shows a greater impact on survival than disease stage. The large experience of the Spanish National Tumor Registry (RGETNE)Elena Martin-Perez, Jaume Capdevila, Daniel Castellano, et al.
The Oncologist|February 12, 2020
The PALBONET Trial: A Phase II Study of Palbociclib in Metastatic Grade 1 and 2 Pancreatic Neuroendocrine Tumors (GETNE-1407)Enrique Grande, Alex Teulé, Teresa Alonso-Gordoa, et al.
Frontiers in Endocrinology|July 17, 2024
Safety and efficacy of nintedanib as second-line therapy for patients with differentiated or medullary thyroid cancer progressing after first-line therapy. A randomized phase II study of the EORTC Endocrine Task Force (protocol 1209-EnTF)Sophie Leboulleux, Ellen Kapiteijn, Saskia Litière, et al.
American Journal of Clinical Dermatology|October 8, 2024
Pembrolizumab for the First-Line Treatment of Recurrent Locally Advanced or Metastatic Merkel Cell Carcinoma: Results from the Single-Arm, Open-Label, Phase III KEYNOTE-913 StudyLaurent Mortier, Lisa Villabona, Ben Lawrence, et al.
Cell Reports|August 4, 2023
DPPA3-HIF1α axis controls colorectal cancer chemoresistance by imposing a slow cell-cycle phenotypeEstefania Cuesta-Borràs, Cándida Salvans, Oriol Arqués, et al.
The New England Journal of Medicine|February 11, 2011
Everolimus for advanced pancreatic neuroendocrine tumorsJames C Yao, Manisha H Shah, Tetsuhide Ito, et al.
Pageof 20

Showing results (131-140 of 192) with videos related to

Sort By:
Pageof 20
BMC Cancer|July 4, 2015
Evaluation of the efficacy and safety of lanreotide in combination with targeted therapies in patients with neuroendocrine tumours in clinical practice: a retrospective cross-sectional analysisJaume Capdevila, Isabel Sevilla, Vicente Alonso, et al.
The Oncologist|December 16, 2017
Phase II Study of BEZ235 versus Everolimus in Patients with Mammalian Target of Rapamycin Inhibitor-Naïve Advanced Pancreatic Neuroendocrine TumorsRamon Salazar, Rocio Garcia-Carbonero, Steven K Libutti, et al.
European Journal of Cancer (Oxford, England : 1990)|February 3, 2026
Larotrectinib in patients with tropomyosin receptor kinase fusion solid tumors in Spain (SPAINTRK)Jorge Hernando, Carlos Lopez, Alejandro Garcia-Alvarez, et al.
Molecular Oncology|June 16, 2017
Analysis of mutant allele fractions in driver genes in colorectal cancer - biological and clinical insightsRodrigo Dienstmann, Elena Elez, Guillem Argiles, et al.
Neuroendocrinology|August 31, 2013
Prognostic factors and long-term outcome of pancreatic neuroendocrine neoplasms: Ki-67 index shows a greater impact on survival than disease stage. The large experience of the Spanish National Tumor Registry (RGETNE)Elena Martin-Perez, Jaume Capdevila, Daniel Castellano, et al.
The Oncologist|February 12, 2020
The PALBONET Trial: A Phase II Study of Palbociclib in Metastatic Grade 1 and 2 Pancreatic Neuroendocrine Tumors (GETNE-1407)Enrique Grande, Alex Teulé, Teresa Alonso-Gordoa, et al.
Frontiers in Endocrinology|July 17, 2024
Safety and efficacy of nintedanib as second-line therapy for patients with differentiated or medullary thyroid cancer progressing after first-line therapy. A randomized phase II study of the EORTC Endocrine Task Force (protocol 1209-EnTF)Sophie Leboulleux, Ellen Kapiteijn, Saskia Litière, et al.
American Journal of Clinical Dermatology|October 8, 2024
Pembrolizumab for the First-Line Treatment of Recurrent Locally Advanced or Metastatic Merkel Cell Carcinoma: Results from the Single-Arm, Open-Label, Phase III KEYNOTE-913 StudyLaurent Mortier, Lisa Villabona, Ben Lawrence, et al.
Cell Reports|August 4, 2023
DPPA3-HIF1α axis controls colorectal cancer chemoresistance by imposing a slow cell-cycle phenotypeEstefania Cuesta-Borràs, Cándida Salvans, Oriol Arqués, et al.
The New England Journal of Medicine|February 11, 2011
Everolimus for advanced pancreatic neuroendocrine tumorsJames C Yao, Manisha H Shah, Tetsuhide Ito, et al.
Pageof 20